UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status Completed
Unique ID issued by UMIN UMIN000036861
Receipt No. R000041992
Scientific Title Comparative efficacy of brigatinib and alectinib in ALK-rearrangement advanced non-small cell lung cancer with central nervous system metastasis: a network meta-analysis of phase3 randomized trials
Date of disclosure of the study information 2019/05/28
Last modified on 2019/06/25

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title Comparative efficacy of brigatinib and alectinib in ALK-rearrangement advanced non-small cell lung cancer with central nervous system metastasis: a network meta-analysis of phase3 randomized trials
Acronym brigatinib veusus alectinib in NSCLC
Scientific Title Comparative efficacy of brigatinib and alectinib in ALK-rearrangement advanced non-small cell lung cancer with central nervous system metastasis: a network meta-analysis of phase3 randomized trials
Scientific Title:Acronym brigatinib veusus alectinib in NSCLC
Region
Japan

Condition
Condition non-small cell lung cancer
Classification by specialty
Pneumology
Classification by malignancy Malignancy
Genomic information NO

Objectives
Narrative objectives1 To compare the efficacy of brigatinib and alectinib in ALK-arrangement advanced non-small cell lung cancer with central nervous system metastasis.
Basic objectives2 Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes Progression free survival(PFS)
Key secondary outcomes Objective response rate(ORR)

Base
Study type Others,meta-analysis etc

Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
18 years-old <=
Age-upper limit

Not applicable
Gender Male and Female
Key inclusion criteria phase3 studies of brigatinib or alectinib in patients with ALK positive advanced non-small cell lung cancer
Key exclusion criteria Studies of patients with double cancer, immunecompromised patients, patients of poor performance status, and patients previously treated with ALT-TKIs
Target sample size 500

Research contact person
Name of lead principal investigator
1st name Koichi
Middle name
Last name Ando
Organization Showa University School of Medicine
Division name Department of Medicine, Division of Respiratory Medicine and Allergology,
Zip code 142-8555
Address 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8555, Japan
TEL 03-3784-8000
Email koichi-a@med.showa-u.ac.jp

Public contact
Name of contact person
1st name Koichi
Middle name
Last name Ando
Organization Showa University School of Medicine
Division name Department of Medicine, Division of Respiratory Medicine and Allergology,
Zip code 142-8555
Address 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8555, Japan
TEL 03-3784-8000
Homepage URL
Email koichi-a@med.showa-u.ac.jp

Sponsor
Institute Showa University School of Medicine, Department of Medicine, Division of Respiratory Medicine and Allergology,
Institute
Department

Funding Source
Organization Showa University School of Medicine, Department of Medicine, Division of Respiratory Medicine and Allergology,
Organization
Division
Category of Funding Organization Other
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization Showa University School of Medicine
Address 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8555, Japan
Tel 03-3784-8000
Email koichi-a@med.showa-u.ac.jp

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2019 Year 05 Month 28 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled 785
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Completed
Date of protocol fixation
2019 Year 04 Month 10 Day
Date of IRB
2019 Year 04 Month 17 Day
Anticipated trial start date
2019 Year 05 Month 12 Day
Last follow-up date
2019 Year 12 Month 16 Day
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information Background: There are few reports comparing the efficacy and safety of ALK gene translocation positive (ALK positive) advanced non-small cell lung cancer (NSCLC) with central nervous system metastasis (CM) between brigatinib and alectinib. Objective: To compare the efficacy and safety for ALK positive NSCLC with CM between brigatinib group (group B) and alectinib group (group A). Methods: Network meta-analysis (indirect comparison) of phase 3 test was performed, and subset analysis for CM cases was performed. The primary efficacy endpoint was progression-free survival (PFS), and the primary safety endpoint was Grade 3-5 adverse events (G3-5 AAEs). Results Three trials (n = 785) were included in this analysis. There was no significant difference in PFS between groups B and A [HR (95% CI) = 0.600 (0.211 to 1.363)]. The surface under the cumulative ranking curve (SUCRA), which is an indicator of relative efficacy, showed a better tendency in group B than in group A [SUCRA = 0.953 (group B) vs 0.547 (group A)]. The frequency of G3-5AAEs did not differ significantly between the two groups. Conclusion: Brigatinib has a relatively good efficacy profile for ALK positive non-small cell lung cancer with central nervous system metastasis, although it is not significant, compared with alectinib, and it is considered to be well tolerated. Further clinical studies are needed to validate the efficacy and safety of brigatinib for ALK positive advanced non-small cell lung cancer with central nervous system metastasis.

Management information
Registered date
2019 Year 05 Month 27 Day
Last modified on
2019 Year 06 Month 25 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000041992

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.